The legislation also significantly redesigns the Medicare Part D prescription drug program, including major changes to the coverage gap discounts currently paid by manufacturers, to the subsidies CMS provides to Part D plans and to the benefit design, and adds requirements for manufacturers to pay new “inflation rebates” on utilization of drugs covered under Medicare Part B or and Part D under certain circumstances. Such changes will have important implications for drug manufacturers, plan sponsors, pharmacies, drug distributors, pharmacy benefit managers and other industry participants, as well as for patients.

Please join members of Reed Smith’s health care team for the second webinar in a three-part series that is focused on providing a detailed analysis of and practical guidance related to the drug pricing provisions included in the IRA. This webinar will focus on the Part D benefit, subsidy, and manufacturer discount redesign. Our team members – who have focused on drug pricing regulations for decades – will help manufacturers and other industry participants to understand how they will be impacted by these changes and what steps they need to take now to prepare for these measures taking effect.